HC Wainwright & Co. analyst Robert Burns downgrades Neoleukin Therapeutics (NASDAQ:NLTX) from Buy to Neutral.
CrossAmerica Partners Q2 EPS $0.35 Beats $0.33 Estimate, Sales $1.48B Up From $859.33M YoY
CrossAmerica Partners (NYSE:CAPL) reported quarterly earnings of $0.35 per share which beat the analyst consensus estimate of $0.33 by 6.06 percent. This is a 169.23 percent increase over earnings of $0.13 per share from
